AAM Statement in Response to FDA's Competitive Generic Therapy (CGT) Designation | Association for Accessible Medicines
SPEAKERS ANNOUNCED - Register for GRx+Biosims 2018 on Sept. 5-7 now

AAM Statement in Response to FDA's Competitive Generic Therapy (CGT) Designation

"We applaud Commissioner Gottlieb and the FDA for recognizing the critical role generics play in helping to control overall drug costs. Generic manufacturers have responded to the Administration's efforts to increase competition through the new CGT pathway and remain committed to working to ensure that safe, effective and more affordable FDA-approved generics are accessible to patients and providers. This pathway, created through FDARA, is a better long-term sustainable solution than considering bringing in drugs from foreign markets."

Attribute to: Chip Davis, President and CEO

MEDIA CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.